Deep dive · 9 min read

Tesamorelin: The Only FDA-Approved "GH Peptide" and What That Means

It is the one growth-hormone-axis peptide that cleared an FDA trial gauntlet for a fat-loss endpoint, and the fine print is more interesting than the headline.

By PepCue Editorial · evidence-checked · no dosing advice

Key takeaways

Tesamorelin (EGRIFTA) is the only GHRH-pathway "GH peptide" with FDA approval for a fat-loss endpoint — and only for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, approved in November 2010.
The pivotal Falutz NEJM 2007 trial (412 patients, PMID 18057338) showed a 15.2% reduction in CT-measured visceral fat versus a 5.0% increase on placebo over 26 weeks, with IGF-1 up 81% and no worsening of glucose.
The benefit does not last after stopping: extension data (PMID 18690162, PMID 20101189) show visceral fat reaccumulates when patients switch to placebo, making tesamorelin a maintenance therapy rather than a one-time fix.
The FDA label is deliberately narrow — it states tesamorelin is NOT indicated for weight-loss management, that long-term cardiovascular safety is not established, and that no data support improved antiretroviral compliance.
It is contraindicated in active malignancy, pregnancy, hypothalamic-pituitary axis disruption, and known hypersensitivity, reflecting the theoretical risks of stimulating the GH/IGF-1 axis.
Research into reducing liver fat in HIV-associated NAFLD (Lancet HIV 2019) is promising but remains a surrogate endpoint in a specific population — encouraging signal, not proven outcome benefit, and no new approval.

Why "the only FDA-approved GH peptide" is a real distinction

The peptide world is full of compounds that nudge the growth hormone (GH) axis — secretagogues and GH-releasing hormone (GHRH) analogs that promise to release your own GH instead of injecting recombinant GH directly. Almost none of them have been approved by a regulatory agency for anything. Tesamorelin, sold as EGRIFTA (and later EGRIFTA SV and EGRIFTA WR), is the exception. It is a stabilized synthetic analog of human GHRH, and in November 2010 the FDA approved it as the first drug for a single, narrow indication: reducing excess visceral abdominal fat in adults living with HIV who have lipodystrophy.

That matters because approval is not a marketing word. It means a sponsor ran adequate and well-controlled human trials, hit a pre-specified primary endpoint, and convinced reviewers the benefit-risk math worked for a defined population. Tesamorelin is essentially the only case where a GHRH-pathway peptide cleared that bar for a body-composition endpoint. Everything else marketed as a "GH peptide" — the various secretagogues you see sold for research use — sits outside that framework. So when tesamorelin is called the only FDA-approved GH peptide, the claim is narrow but accurate, and the narrowness is the whole story.

What HIV-associated lipodystrophy actually is

To understand the approval you have to understand the disease it treats, which is not general belly fat. In the early antiretroviral era, many people on long-term HIV therapy developed a striking redistribution of body fat: subcutaneous fat melted away from the face, arms, and legs while visceral adipose tissue (VAT) — the deep fat packed around the abdominal organs — accumulated, sometimes dramatically, along with dorsocervical fat pads. This is HIV-associated lipodystrophy.

Visceral fat is the metabolically dangerous kind. It is associated with dyslipidemia, insulin resistance, and elevated cardiovascular risk, and in this population it was both disfiguring and difficult to treat: diet and exercise help modestly, and you cannot simply liposuction visceral fat. People with HIV also tend to have blunted GH secretion, and GH is one of the body's signals for mobilizing visceral fat. That biological gap is the rationale tesamorelin was built on — restore a more normal GHRH pulse, let the patient's own pituitary release GH, and preferentially mobilize VAT. The drug was designed for a specific metabolic lesion in a specific population, which is exactly why its label is so tightly drawn.

The pivotal Falutz trial: what the numbers really were

The cornerstone evidence is a phase 3 randomized, double-blind, placebo-controlled trial led by Julian Falutz and colleagues, published in the New England Journal of Medicine in 2007 (Falutz J et al., N Engl J Med 2007;357:2359-70; PMID 18057338). It randomized 412 patients with HIV and abdominal fat accumulation to daily subcutaneous tesamorelin or placebo for 26 weeks, with VAT measured by CT as the primary endpoint.

The result is where the widely cited ~15% figure comes from. Visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group over 26 weeks. IGF-1 — the downstream marker confirming the GH axis was actually being stimulated — rose by 81.0% on tesamorelin while falling 5.0% on placebo. Triglycerides improved, and, importantly, the trial reported no significant differences in glycemic measures between groups, addressing a real worry with GH-axis drugs (GH can worsen glucose tolerance). A second, similarly designed phase 3 trial of 404 patients reinforced the pattern (Falutz J et al., J Acquir Immune Defic Syndr 2010; PMID 20101189). Two convergent randomized trials hitting the same CT-confirmed endpoint is precisely the kind of replicated, objective evidence regulators want — and it is what most "GH peptides" lack entirely.

The catch that defines the drug: benefits vanish when you stop

Here is the honest part that rarely makes it into supplement-style write-ups. Tesamorelin does not reset your body's set point for visceral fat. It actively mobilizes VAT only while you keep taking it. The trials built in extension phases specifically to test durability, and the answer was unambiguous: the benefit does not persist after stopping.

In the 52-week safety extension of the first pivotal program, patients who were switched from tesamorelin to placebo at week 26 saw their visceral fat reaccumulate — the abstract states plainly that "upon discontinuation of tesamorelin, VAT reaccumulated" (Falutz J et al., AIDS 2008; PMID 18690162). The second phase 3 trial reported the same thing in different words: the initial 6-month improvements in VAT were "rapidly lost in those switching from tesamorelin to placebo" (PMID 20101189). This reframes the entire product. Tesamorelin is not a short course that buys durable change; it is a maintenance therapy. Stop it, and the deep fat comes back over months. That single fact is the most important thing to understand about it, and it should temper any expectation that a GHRH peptide produces lasting body recomposition once discontinued.

Why the FDA label is deliberately narrow

Read the actual prescribing information and the restraint is obvious. EGRIFTA SV is "indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy" — full stop. The Limitations of Use section then closes the doors people most want to walk through. It states that long-term cardiovascular safety has not been established; that the drug is not indicated for weight-loss management (it is weight-neutral, it redistributes rather than reduces total mass); and that there are no data supporting improved compliance with antiretroviral therapy. In other words, the label refuses to claim a hard outcome benefit — it is approved on a surrogate, the change in visceral fat measured by CT, not on reduced heart attacks or longer survival.

The contraindications round out the caution. Tesamorelin is contraindicated in people with disruption of the hypothalamic-pituitary axis, in active malignancy (because stimulating GH/IGF-1 in the presence of cancer is a theoretical growth risk), in known hypersensitivity, and in pregnancy. None of this is hidden — it is the FDA explicitly drawing a box around the one population and one endpoint the evidence actually supports, and declining to extrapolate beyond it.

The research frontier: liver fat, and why "promising" is not "proven"

The most scientifically interesting work beyond the original indication concerns the liver. Because visceral fat and ectopic liver fat track together, researchers tested whether tesamorelin could reduce hepatic fat and affect non-alcoholic fatty liver disease (NAFLD) in people with HIV. A randomized, double-blind, multicenter trial published in Lancet HIV in 2019 (Stanley TL et al.) reported that tesamorelin reduced liver fat over 12 months and was associated with less fibrosis progression in this population. That is a genuinely meaningful signal, and it has driven continued investigation.

But the boundaries matter. This was studied in people with HIV, not the general NAFLD/NASH population; the trials are modest in size; and reducing liver fat on imaging is, again, a surrogate — not the same as preventing cirrhosis, liver cancer, or death. None of this liver work has produced a new FDA approval. The line to hold is the one this whole article keeps returning to: mechanistic and even randomized human evidence for a surrogate is encouraging, but it is not the same as a proven outcome benefit, and it does not extend the approved use beyond HIV-associated lipodystrophy.

What this means for how people read "GH peptides"

Tesamorelin is the cleanest test case the GH-peptide category has, and the lessons cut against the marketing. First, the approved benefit is real but specific: roughly a 15% CT-measured reduction in visceral fat, in adults with HIV and lipodystrophy, while taking the drug. Second, it is maintenance-dependent — the effect reverses on discontinuation, so it does not deliver durable recomposition. Third, even with two replicated phase 3 trials, regulators approved it on a surrogate and explicitly declined to claim cardiovascular or mortality benefit.

Now contrast that with the broader market. The many other peptides sold as GH secretagogues or GHRH analogs for "research use" have not cleared anything close to this evidentiary bar for a body-composition endpoint, and several are not approved for human therapeutic use at all. If the single peptide that did run the full gauntlet ended up with a narrow indication, a surrogate endpoint, a not-for-weight-loss disclaimer, and a benefit that disappears on stopping — that is the realistic ceiling, not the floor, for how much to expect from this class. The honest takeaway is not that tesamorelin is weak; it is that it is the rare one whose strengths and limits are actually documented.

FAQ

Is tesamorelin approved for weight loss?

No. The FDA label explicitly states EGRIFTA SV is not indicated for weight-loss management. It is weight-neutral — it redistributes fat by reducing visceral (deep abdominal) fat rather than reducing total body weight, and its only approved use is reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.

How much visceral fat does tesamorelin actually reduce?

In the pivotal NEJM 2007 trial of 412 patients (PMID 18057338), CT-measured visceral adipose tissue dropped 15.2% on tesamorelin over 26 weeks, while it rose 5.0% on placebo. A second phase 3 trial of 404 patients confirmed a similar effect. These figures apply specifically to adults with HIV and lipodystrophy on antiretroviral therapy.

Does the visceral fat come back if you stop tesamorelin?

Yes. The trial extension data are clear that the effect is not durable. In the 52-week extension (PMID 18690162), visceral fat reaccumulated after discontinuation, and the second phase 3 trial (PMID 20101189) reported the gains were rapidly lost when patients switched to placebo. Tesamorelin works only while it is being taken.

Why is tesamorelin only approved for people with HIV?

It was developed for HIV-associated lipodystrophy, a specific syndrome of fat redistribution and blunted growth hormone secretion seen with long-term HIV therapy. The pivotal trials enrolled only that population, so that is the only population where the benefit-risk balance was demonstrated. The FDA approved the narrow indication the evidence actually supported and did not extrapolate further.

What about tesamorelin for fatty liver disease?

A randomized Lancet HIV 2019 trial found tesamorelin reduced liver fat and was associated with less fibrosis progression in people with HIV and NAFLD. That is a meaningful research signal, but it is a surrogate endpoint in a specific population, the studies are small, and it has not produced any new FDA approval. It should not be read as proven outcome benefit.

Is tesamorelin the same as other GH-releasing peptides sold online?

No. Tesamorelin is a specific, FDA-approved, stabilized GHRH analog with replicated phase 3 human trials behind it. Many other compounds marketed as GH secretagogues or GHRH analogs are sold for research use, lack comparable human trial evidence for body-composition endpoints, and are not approved for therapeutic human use.

Sources

[1]Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV (pivotal Falutz phase 3 trial) — Falutz J, et al. N Engl J Med. 2007;357:2359-70. PMID 18057338
[2]Long-term safety and effects of tesamorelin in HIV patients with abdominal fat accumulation (52-week extension; VAT reaccumulation after discontinuation) — Falutz J, et al. AIDS. 2008. PMID 18690162
[3]Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: randomized trial with a safety extension (second phase 3 trial) — Falutz J, et al. J Acquir Immune Defic Syndr. 2010. PMID 20101189
[4]EGRIFTA SV (tesamorelin) — FDA prescribing information / label (indication, limitations of use, contraindications) — DailyMed, U.S. National Library of Medicine
[5]Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial — Stanley TL, et al. Lancet HIV. 2019 (full text via PMC)

Go deeper

See where every compound ranks

The PepCue tier board grades 48 compounds S–F by published evidence — with cited sources on every one.

Open the tier board →